Non-squamous Non-small-cell Lung Cancer Clinical Trial
Official title:
A Randomized, Double-blind, Parallel-controlled Study Comparing the Efficacy and Safety of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (SIBP04) and Bevacizumab Injection (Avastin) in Combination With Paclitaxel and Carboplatin Respectively in Patients With Advanced, Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer.
This trial is a randomized, double-blind, parallel-controlled, multicenter phase III clinical study. To evaluate the clinical efficacy of SIBP04 in patients with locally advanced, metastatic or recurrent non-squamous non-small cell lung cancer.
This trial is a randomized, double-blind, parallel-controlled, multicenter phase III clinical study. The study was divided into three stages: screening stage, treatment stage (combined chemotherapy stage, single drug maintenance treatment stage, visit after treatment) and follow-up stage (survival follow-up after disease progression). To evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of SIBP04 in patients with locally advanced, metastatic or recurrent non-squamous non-small cell lung cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04504916 -
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)
|
Phase 2 | |
| Not yet recruiting |
NCT05849246 -
The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
|
Phase 2 | |
| Active, not recruiting |
NCT04396457 -
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901
|
Phase 2 | |
| Recruiting |
NCT05338619 -
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy
|
Phase 2 | |
| Terminated |
NCT04265534 -
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT05258279 -
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
|
Phase 2 | |
| Not yet recruiting |
NCT04453423 -
Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.
|
Phase 2 | |
| Terminated |
NCT04173338 -
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
|
Phase 1 | |
| Terminated |
NCT04698681 -
NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
|
||
| Active, not recruiting |
NCT04211090 -
Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC
|
Phase 2 | |
| Recruiting |
NCT04619433 -
A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.
|
Phase 3 | |
| Recruiting |
NCT04084717 -
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT04958811 -
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
|
Phase 2 | |
| Completed |
NCT00152477 -
A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
|
Phase 2 | |
| Completed |
NCT04012619 -
Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05403554 -
A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers
|
Phase 1 |